Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

ConferenceIvonescimabPositive

AI Analysis

Summary

Akeso announced that its Phase III ivonescimab overall survival data for first-line biliary tract cancer has been selected as a late-breaking abstract at ESMO 2026, with nearly 30 Akeso clinical studies to be presented at the congress.

Clinical Trial Data

Phase

Phase_3

Outcome Details

Overall survival data selected as late-breaking abstract at ESMO 2026

Importance:6/10

Sentiment:

0.60

ESMO 2026late-breaking abstractbispecific antibodybiliary tract cancerphase IIIoverall survival

Related Companies

$DFPH $MDCE $TRAX

Read the original article

Published by PR Newswire Biotech on September 21, 2026 11:46 PM

Read Original